Objective To present a summary of the 2020 version of the European Association of Urology
(EAU)-European Association of Nuclear Medicine (EANM)-European Society for …

Background The median age of prostate cancer diagnosis is 66 years, and the median age
of men who die of the disease is eighty years. The public health impact of prostate cancer is …

Context The optimal treatment for men with high-risk localized or locally advanced prostate
cancer (PCa) remains unknown. Objective To perform a systematic review of the existing …

Thermal tumor ablation techniques including radiofrequency, microwave, LASER, high-
intensity focused ultrasound and cryoablation are routinely used to treated liver, kidney …

Objective The objective of the French Urology Association Cancer Committee is to propose
an update of the recommendations for the diagnosis and management of prostate cancer …

Prostate cancer focal therapy is an attractive option for well-selected patients because of its
low complication profile; however, long-term oncologic outcome is still lacking and early …

Prostate cancer (PCa) is one of the first three causes of cancer mortality in Europe.
Screening in asymptomatic men (aged 55–69 yr) using prostate-specific antigen (PSA) is …

Objective To report medium‐term oncological outcomes in men receiving primary focal
treatment with high‐intensity focused ultrasonography (HIFU) for prostate cancer (PC a) …

Active surveillance (AS) represents a well-recognized management option for many patients
with low-and very low-risk prostate cancer (PCa). AS aims to reduce overtreatment whilst …

Background Focal irreversible electroporation (IRE) can be used to treat men with localised
prostate cancer (PCa) with reduced impact on quality of life (QoL). Objective To assess …